Condition (MeSH)
Takotsubo Cardiomyopathy
ClinicalTrials.gov lists 63 trials for Takotsubo Cardiomyopathy or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
63 of the 63 trials are tagged with Takotsubo Cardiomyopathy itself; the rest are tagged with a narrower condition beneath it.
When did Takotsubo Cardiomyopathy trials start? (21)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1/2
- Phase 2
- Phase 4
- Not applicable
- Observational
Top of scale: 6
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2025 | 5 |
| 2024 | 5 |
| 2023 | 4 |
| 2022 | 4 |
| 2021 | 3 |
| 2020 | 5 |
| 2019 | 5 |
| 2018 | 3 |
| 2017 | 2 |
Showing 10 of 21 earlier years.
No forecast is made for this condition: it averages 4.2 trial starts a year over the five years to September, under the 5 a year the method needs.
Prediction, not a registry value: median of 36 months from start to primary completion across 5 trials still running at the 2026-10-09 snapshot; registered median of 36 months across 28 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Takotsubo Cardiomyopathy trials in? (5)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1/2 | 1 |
| Phase 2 | 2 |
| Phase 4 | 3 |
| Not applicable | 18 |
| Observational | 39 |
How many Takotsubo Cardiomyopathy trials are recruiting? (6)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 3 |
| Recruiting | 21 |
| Active, not recruiting | 2 |
| Completed | 24 |
| Terminated | 2 |
Showing 5 of 6 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which drugs are being tested for Takotsubo Cardiomyopathy? (1)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Adenosine | 2 |
Interventions as named in the registry (14)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| The Modified Oxford Technique for Baroreflex Sensitivity | 1 |
| Metoprolol XL | 1 |
| Beta Blocker | 1 |
| Cyclosporine 0.05% | 1 |
| Apixaban IR | 1 |
Showing 5 of 14 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Takotsubo Cardiomyopathy trials report? (1)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Takotsubo Syndrome recurrence | 1 | 1 |
Which publications cover Takotsubo Cardiomyopathy? (119)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Rationale and design of the beta-blockers in tako-tsubo syndrome study: a randomized clinical trial (β-Tako). | Revista espanola de cardiologia (English ed.) | 2025 | Yes |
| Beta-Blockers and Long-Term Mortality in Takotsubo Syndrome: Results of the Multicenter GEIST Registry. | JACC. Heart failure | 2025 | Yes |
| Prospective comparison of temporal changes in myocardial function in women with Takotsubo versus anterior STEMI. | Clinical research in cardiology : official journal of the German Cardiac Society | 2025 | Yes |
| Rationale and design of the cyclosporine in Takotsubo syndrome (CIT) trial. | American heart journal | 2025 | Yes |
| Prognostic Value of Microvascular Function in Takotsubo Syndrome: A Pooled Analysis of Individual Patient Data. | JACC. Cardiovascular interventions | 2025 | Yes |
Showing 5 of 119 publications.
Prevalence (6)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Tako-Tsubo cardiomyopathy | Annual incidence | 1-9 / 100 000 | France | Not stated | Exact |
| Tako-Tsubo cardiomyopathy | Annual incidence | 1-9 / 100 000 | France | Not stated | Unspecified |
| Tako-Tsubo cardiomyopathy | Point prevalence | Unknown | Worldwide | Not stated | Exact |
| Tako-Tsubo cardiomyopathy | Point prevalence | Unknown | Worldwide | Not stated | Unspecified |
| Tako-Tsubo cardiomyopathy | Annual incidence | 1-9 / 100 000 | France | Not stated | Exact |
Showing 5 of 6 prevalence observations.
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Tako-Tsubo cardiomyopathy | 66529 | Exact | Orphanet Rare Disease Ontology (ORDO) |
| Tako-Tsubo cardiomyopathy | 66529 | Exact | Orphadata Science knowledge files, Product 1 |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: lead sponsors and sub-conditions in mesh.